Tumor Necrosis Factor-alpha
"Tumor Necrosis Factor-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.
| Descriptor ID |
D014409
|
| MeSH Number(s) |
D12.644.276.374.500.800 D12.644.276.374.750.626 D12.776.124.900 D12.776.395.930 D12.776.467.374.500.800 D12.776.467.374.750.626 D23.529.374.500.800 D23.529.374.750.626
|
| Concept/Terms |
Tumor Necrosis Factor-alpha- Tumor Necrosis Factor-alpha
- Tumor Necrosis Factor alpha
- Cachectin
- Cachectin-Tumor Necrosis Factor
- Cachectin Tumor Necrosis Factor
- Tumor Necrosis Factor Ligand Superfamily Member 2
- Tumor Necrosis Factor
- TNF Superfamily, Member 2
- TNFalpha
- TNF-alpha
|
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factor-alpha".
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factor-alpha".
This graph shows the total number of publications written about "Tumor Necrosis Factor-alpha" by people in this website by year, and whether "Tumor Necrosis Factor-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 1996 | 1 | 1 | 2 |
| 1997 | 3 | 3 | 6 |
| 1998 | 1 | 4 | 5 |
| 1999 | 2 | 7 | 9 |
| 2000 | 2 | 3 | 5 |
| 2001 | 0 | 2 | 2 |
| 2002 | 5 | 3 | 8 |
| 2003 | 3 | 3 | 6 |
| 2004 | 4 | 3 | 7 |
| 2005 | 2 | 3 | 5 |
| 2006 | 2 | 3 | 5 |
| 2007 | 1 | 4 | 5 |
| 2008 | 1 | 5 | 6 |
| 2009 | 2 | 0 | 2 |
| 2010 | 0 | 4 | 4 |
| 2011 | 2 | 2 | 4 |
| 2012 | 1 | 3 | 4 |
| 2013 | 0 | 5 | 5 |
| 2014 | 1 | 2 | 3 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 2 | 2 |
| 2017 | 1 | 4 | 5 |
| 2018 | 1 | 2 | 3 |
| 2019 | 3 | 1 | 4 |
| 2020 | 1 | 2 | 3 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Necrosis Factor-alpha" by people in Profiles.
-
Cytokine storm-based mechanisms for extrapulmonary manifestations of SARS-CoV-2 infection. JCI Insight. 2023 05 22; 8(10).
-
Biodegradable Microspheres and Hydrogel Drug Delivery System of Tumor Necrosis Factor (TNF) Inhibitor and Growth Differentiation Factor 5 (GDF5) Reduces Disk Inflammation in the Rabbit Model. Spine (Phila Pa 1976). 2023 Aug 01; 48(15):E257-E265.
-
Chemokine Regulation in Temporomandibular Joint Disease: A Comprehensive Review. Genes (Basel). 2023 02 04; 14(2).
-
Contribution of Innate Lymphoid Cells in Supplementing Cytokines Produced by CD4+ T Cells During Acute and Chronic SIV Infection of the Colon. AIDS Res Hum Retroviruses. 2022 09; 38(9):709-725.
-
Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson's disease: A case series. Neurobiol Dis. 2020 10; 144:105027.
-
Biosimilar infliximab administration for the management of acute graft-versus-host disease. J Oncol Pharm Pract. 2020 Dec; 26(8):2047-2051.
-
Presence of Inflammatory Group I and III Innate Lymphoid Cells in the Colon of Simian Immunodeficiency Virus-Infected Rhesus Macaques. J Virol. 2020 04 16; 94(9).
-
Chronic rhinosinusitis precipitated by tumor necrosis factor alpha inhibitors is the phenotype of chronic rhinosinusitis without nasal polyps. Int Forum Allergy Rhinol. 2020 01; 10(1):23-28.
-
Children with Narcolepsy type 1 have increased T-cell responses to orexins. Ann Clin Transl Neurol. 2019 12; 6(12):2566-2572.
-
Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: a systematic review. Int J Dermatol. 2020 May; 59(5):520-524.